PRT2527: a phase 1 trial of PRT2527 in people with relapsed or refractory B-cell lymphomas

This trial is testing PRT2527 in people with certain lymphomas which have returned after (relapsed) or not responded to (refractory) treatment, when given on its own, and in combination with zanubrutinib.

You can share the following ClinicalTrials.gov Identifier with your medical team so they can find out more about the trial: NCT05665530

Trial aim and background

The aim of this trial is to find out how safe and effective the medication PRT2527 is when given on its own, or in combination with zanubrutinib in people with the following lymphomas:

  • Aggressive B-cell lymphomas
  • Mantle cell lymphoma (MCL)
  • Chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL)
  • T-cell lymphomas

The trial will be in two parts:

  • Phase 1 will involve escalating doses of PRT2527 on its own or with zanubrutinib.
  • Phase 2 will involve the dose being given to specific group of patients to confirm it.  

PRT2527 is a CDK9 inhibitor. CDK9 plays an important role in the activation of cancer cells. 

Zanubrutinib is a type of targeted drug called a BTK inhibitor.

This is a phase 1 (early phase) trial. Little is known about the safety and effectiveness of this treatment. You might not benefit from the treatment, but the trial will give important information about this new treatment, which could help other people in the future.

Who can enter

Adults with relapsed or refractory aggressive B-cell lymphomas, MCL, CLL/SLL or T-cell lymphomas may be eligible for this trial.

Locations

Recruitment is taking place at St James University Hospital in Leeds.

Further information

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://www.clinicaltrials.gov/study/NCT05665530

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.